Cell Line Development Inefficiencies And Streamlining The Clone Selection Process For Protein Biologic Production With The Solentim® Ecosystem

By Adam Causer, PhD., Chloe Harris, MSc., Dan Jones, MSc., Qi Zhang, MSc., Jessica Turner, Emma Morris, BSc., Anna Davidson, MSc. & Camilla Domeneghetti, MRes.

As the demand for innovative protein-based biotherapeutics rises, pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) must prioritize increasing efficiency and boosting productivity within their cell line development (CLD) workflows. A major hurdle in this process is creating stable cell lines that can express increasingly complex proteins while maintaining high cell viability from single-cell to bioreactor expansion. Common pain points include a lack of clonality assurance, clone death during expansion resulting in false-positive titers, and the time-intensive and expensive methods used to quantify critical quality attributes (CQAs), like glycosylation profiles. Traditional methods to overcome these challenges often involve labor-intensive data consolidation from multiple instruments, leading to higher labor costs and limited project throughput. Read on to learn about a powerful solution that leverages cutting-edge imaging technology to provide robust evidence of clonality, precise confluence quantitation, and rapid viable cell density assays. Its high-throughput, low-volume assays enable fast measurement of both titers and glycosylation profiles in IgG and Fc-containing proteins.